Clinical Trial Update: Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting safety and efficacy findings for MBX-102 in treating hyperuricemia in patients with gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• MBX-102

Snippet

Sponsor: Gilead Sciences | Conditions: Hyperuricemia, Gout | Phase 2 | Status: COMPLETED